LUMO(Delisted)
Lumos PharmaยทNASDAQ
--
--(--)
LUMO Profile
Lumos Pharma, Inc.
A biopharmaceutical company that develops immunotherapeutic therapy for cancer
4200 Marathon Blvd., Suite 200, Austin, Texas 78756
--
Lumos Pharma, Inc., founded in Delaware on June 4, 1999 as NewLink Genetics Corporation, is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapy products to improve treatment options for cancer patients. The company's products include biological and small molecule immunotherapy products. The Company's biological products are based on the Company's proprietary hyperacute immunotherapy technology, which is designed to stimulate the human immune system. The Company's small molecule products focus on breaking the tolerance of the cancer immune system by inhibiting the indoleamin- (2, 3) -plus dioxygenase pathway. The Company believes that the Company's immunotherapy technology has the potential to generate multiple products for the treatment of a wide range of tumor symptoms that can be treated alone or in combination with therapies.
